16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients
Status:
Completed
Trial end date:
2017-12-11
Target enrollment:
Participant gender:
Summary
The purpose of this study was to generate 16-week efficacy data, as well as up to 3-year
efficacy, safety and tolerability data in subjects with active AS despite current or previous
NSAID, DMARD and/or anti-TNF therapy.